Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

11.56USD
24 Mar 2017
Change (% chg)

-- (--)
Prev Close
$11.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
130,442
52-wk High
$16.29
52-wk Low
$7.20

Latest Key Developments (Source: Significant Developments)

Omeros reports additional positive results from OMS721 Phase 2 trial
Wednesday, 1 Mar 2017 07:00am EST 

Omeros Corp : Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy . Omeros Corp - total of ten serious adverse events have been reported, none considered related to OMS721 treatment . Omeros Corp - two patients died of progression of cancer after less than three weeks of OMS721 treatment . Omeros Corp - one patient died of graft failure after completing study and positively responding to oms721 .Omeros Corp - none of these deaths was considered by investigators to be related to OMS721 treatment..  Full Article

Omeros announces pricing of public offering of common stock
Thursday, 11 Aug 2016 10:49am EDT 

Omeros Corp : Omeros announces pricing of public offering of common stock .Pricing of a $40 million underwritten public offering of its common stock at a price to public of $11.50 per share.  Full Article

Omeros announces public offering of common stock
Wednesday, 10 Aug 2016 04:01pm EDT 

Omeros Corp : Omeros announces public offering of common stock . Intends to use net proceeds for funding research and development expenses for its clinical OMS721 program and clinical trials .Says announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co..  Full Article

Omeros confirms late-stage development plan for OMS721 with EMA
Thursday, 28 Jul 2016 09:27am EDT 

Omeros Corp : Omeros corporation confirms oms721 phase 3 development plan with european medicines agency . Initiation of enrollment in ahus phase 3 clinical trial is planned for late this year . Omeros plans to commercialize oms721 initially for administration as a subcutaneous injection .One single-arm, open-label phase 3 pivotal trial planned to support approval in both europe and u.s..  Full Article

Omeros enters debt financing transaction for $20 mln in additional funds
Tuesday, 17 May 2016 07:00am EDT 

Omeros Corp : Entered into an amendment to its existing credit facility to provide company with an additional $20 million in unrestricted cash . Will issue warrants to lenders, exercisable for 7 years for up to 100,602 shares of common stock at an exercise price per share of $9.94 . Expects funding will occur on may 18, 2016. .Omeros announces debt financing transaction for $20 million in additional funds.  Full Article

Omeros Corporation reports Q1 loss per share $0.54
Tuesday, 10 May 2016 07:29am EDT 

Omeros Corp : Omeros corporation reports first quarter 2016 financial results . Q1 loss per share $0.54 . Q1 revenue $7.4 million versus I/B/E/S view $8.8 million . Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S ."continue to expect that we will reach cash-flow positive status later this year, fully funding our pipeline".  Full Article

Omeros Corp announces exclusive Middle East distribution agreement
Tuesday, 10 May 2016 07:00am EDT 

Omeros Corporation : Omeros Corporation announces exclusive middle east distribution agreement for omidria .Distribution agreement for sale of omidria in Saudi Arabia, UAE and other countries in Middle East with Itrom Trading Drug Store.  Full Article

Omeros Corp Files Infringement Suits Against Par
Thursday, 3 Sep 2015 09:15am EDT 

Omeros Corp:Filed patent infringement lawsuits against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC, (collectively "Par") in the U.S. District Court for the District of New Jersey and in U.S. District Court for the District of Delaware.lawsuits were filed under the Hatch-Waxman Act for Par's infringement of three Omeros patents, U.S. Patent Nos. 8,173,707, 8,586,633 and 9,066,856.which relate to Omeros' drug Omidria(phenylephrine and ketorolac injection) 1%/0.3% and which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book, published by FDA.Under the Hatch-Waxman Act, Omeros was permitted to file suit within 45 days from its receipt of Par's notice and thereby trigger a 30-month stay of the FDA's approval of Par's ANDA.stay is expected to remain in effect until March 2018. Omeros has reviewed Par's Paragraph IV assertions and believes they do not have merit\.Omeros has sought access to Par's ANDA, which Par is legally required to provide under reasonable terms, but to date Par has not provided this access.Omeros will obtain access to Par's ANDA and will vigorously prosecute its infringement claims against Par.  Full Article

Omeros announces additional positive data in OMS721 Phase 2 Clinical Trial
Tuesday, 18 Aug 2015 07:00am EDT 

Omeros Corporation:Announces additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies.  Full Article

Omeros Corp announces plan to file infringement suit against ANDA Filer
Monday, 17 Aug 2015 07:00am EDT 

Omeros Corp:Press release- Omeros announces plan to file infringement suit against ANDA filer.Says plans to file a patent infringement lawsuit against Par Pharmaceutical Inc and its subsidiary, par sterile products, llc.Suit in response to anda filed by par seeking FDA approval to market a generic version of Omeros' commercial drug omidria.  Full Article

More From Around the Web

BRIEF-Omeros reports additional positive results from OMS721 Phase 2 trial

* Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy